Richard H. Scheller joined BridgeBio Pharma as senior advisor and chair of research and development in 2019. He served as a member of the board from 2018 to 2023. In addition, he serves on the board of directors at Alector, Maze Therapeutics, Aarvik Therapeutics, GondolaBio, Xaira Therapeutics, Trace Neuroscience, and on the board of trustees at Caltech and the board of the Corporation of the Fine Arts Museums of San Francisco. He served on the board of directors at Xenon Pharmaceuticals (2015 to 2020), ORIC (2015-2021), 23andMe (2019-2024), and as Chairman of the Board of Directors at DICE Therapeutics (2015-2023). From 2015 to 2019, Dr. Scheller was head of therapeutics and chief scientific officer at 23andMe. At Genentech from 2001 to 2014, he was executive vice president of research and early development and served on the executive committees of Roche and Genentech focusing on research strategy, drug discovery, business development and early drug development activities.  

‍

From 1982 to 2001, Dr. Scheller was a professor at Stanford in the Department of Biological Sciences and the Department of Molecular and Cellular Physiology and was an investigator at the Howard Hughes Medical Institute of Stanford University Medical Center. Since 2004, Dr. Scheller has served as an adjunct professor in the Department of Biochemistry and Biophysics at the University of California, San Francisco.  

He holds a B.S. in biochemistry from the University of Wisconsin-Madison and a Ph.D. in chemistry from Caltech. Scheller’s research elucidating the molecular machinery and regulatory mechanism that underlies neurotransmitter release earned him the 2013 Albert Lasker Basic Medical Research Award, the 2010 Kavli Prize in Neuroscience, and the 1997 U.S. National Academy of Sciences Award in Molecular Biology. He is a fellow of the American Academy of Arts and Sciences, a member of the National Academy of Sciences, and a member of the National Academy of Medicine.

‍